Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, double-blind, placebo-controlled, two-period cross-over
study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment
Periods. All participants with receive both ensifentrine and placebo during participation.
There are 7 in-clinic visits over a total duration of up to 24 weeks participation.